Clinical Trials

Pharmaceutical Outsourcing Clinical Trials Patient Vitals Abstract Image

Clinical trials are conducted to evaluate and test new pharmaceuticals before they are approved and brought to market. Clinical trials were traditionally conducted in three phases, with a fourth phase added to monitor post-marketing findings. The trials at each phase have a different purpose and help researchers evaluate the potential treatment in a number of ways to ensure its safety and efficacy.

Phase I trials

Researchers test an experimental drug or treatment in a small group of people for the first time. The researchers evaluate the treatment’s safety, determine a safe dosage range, and identify side effects.

Phase II trials

The experimental drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

Phase III trials

The experimental study drug or treatment is given to large groups of people. Researchers confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely.

Phase IV trials

Post-marketing studies, which are conducted after a treatment is approved for use by the FDA, provide additional information including the treatment or drug’s risks, benefits, and best use.

Filter

Hide Filter
  • An Evolution Is Underway - And Is Here To Stay - In Centralized Monitoring

    Friday, March 17, 2017
    International Council for Harmonisation Integrated Addendum to ICH E6 R1 - otherwise known as ICH E6 R21 - suggests centralized monitoring be incorporated as an important monitoring methodology in clinical trials. Different companies are taking ... read more
  • A View to Strategic Partnering

    Friday, March 17, 2017
    Any human enterprise is subject to challenge from its conceptual stage; from financial hurdles to technology and expertise, they all contribute to the success or failure of our goals. The typical business cycle dictates that we need to define our ... read more
  • An Interview With... Peter Soelkner, Managing Director, Vetter Pharma International GmbH

    Friday, March 17, 2017
    There has always been a variety of challenges affecting the parenteral manufacturing industry and its participants. read more
  • Clinical Trial Contracts: Language and Limitations

    Friday, March 17, 2017
    Contracts provided to study sites by industry sponsors contain legal language that is often confusing and not well understood by the study site representatives. This article reviews risk areas and contract language that sites should be familiar ... read more
  • The Rising Adoption of Technology in Clinical Trials

    Friday, March 17, 2017
    What’s been proven to reduce data variance, increase patient compliance and decrease site monitoring costs in clinical trials? For certain, it’s not the continued use of paper records. Digitization of clinical trial processes is the driving force ... read more
  • Data Trust and Transparency: New Era of Clinical Outsourcing and Partnerships

    Friday, March 17, 2017
    Demands today and into the next decade for more and better therapies is placing unprecedented pressure on the global pharmaceutical industry, and it is estimated that by 2020, up to three quarters of clinical trials are likely to be performed by CROs... read more
  • Anticipating Future Guidelines By Utilizing The Latest Technologies In Particle Characterization

    Friday, March 17, 2017
    The presence of particulate matter in pharmaceutical products con-tinues to be one of the top reasons for recall. This year, 11 of the 54 safety alerts issued by the FDA were for the presence of particulates in drug and therapeutic biological ... read more
  • Multi-Site Clinical Partnerships: Bringing Together CROs, Sponsors and Hospitals

    Friday, March 17, 2017
    As the biopharmaceutical industry is facing a longer, more complex, and more expensive drug development process, all stakeholders must demonstrate flexibility and the ability to innovate and find solutions to overcome challenges. Patient ... read more
  • Investors May Look Smaller

    Wednesday, March 15, 2017
    The 2017 Nice Insight Life Sciences Private Equity/ Venture Capital Investment Survey highlights some interesting trends in the way investors of all kinds currently look at opportunities in the life science and healthcare sectors. read more
  • Equipment Must Integrate

    Wednesday, March 15, 2017
    Modern pharmaceutical manufacturing equipment and associated analytical instrumentation is the fundamental ‘hardware’ required to produce safe, effective, highquality medicinal products. To meet the challenges from increasingly downward price ... read more
  • Advancing Solid Dose Processing Efficiency and Effectiveness

    Wednesday, March 15, 2017
    Because oral solid dose (OSD) pharmaceuticals will remain the dominant dose form, the pharmaceutical industry will continue to be responsible for the high-quality manufacture of hundreds of millions of individual doses every day, every year ... read more
  • Achieving Security of Supply with Effective Particle Engineering

    Wednesday, March 15, 2017
    Targeted particle engineering for solid dosage drug formulations has become an imperative given the challenging compounds in the pharmaceutical pipeline, the growing interest in inhaled delivery, and the move to continuous manufacturing. Contract ... read more
  • Spending on Excipients Grows & Diversifies

    Wednesday, March 15, 2017
    Pharmaceutical excipients are used in combination with APIs in multiple medicinal products, including tablets, capsules, oral liquids, transdermal patches, implants and inhalers. Traditionally, these excipients were used to add bulk to ... read more
  • Changes In the Wind for the CDMO Market

    Wednesday, March 15, 2017
    The global pharmaceutical market continues to grow at a healthy rate. According to research firm Evaluate Pharma, the global drug market will expand at a compound annual growth rate (CAGR) of 6.3% from 2016 to 2022, with biologics accounting for ... read more
  • Cloud Computing.. Roundtable

    Wednesday, March 15, 2017
    What impact do you think the move to cloud computing will have on the ability of contract service organizations to better QQ meet the needs of their customers? read more